Pipeline

PROGRAM

DISEASE

DISCOVERY

PRE-CLINICAL

PHASE 1/2

PIVOTAL

AML

WU-NK-101

Head & Neck Cancer

WU-NK-101 + Cetuximab

WU-NK

Melanoma

WU-NK-101 (post-checkpoint inhibitor)

Solid Tumors

WU-NK-201

WU-CART

T-ALL

WU-CART-007

AML = Acute Myeloid Leukemia
T-ALL = T-cell Acute Lymphoblastic Leukemia

View Lead Programs

Lead Programs

WU-NK-101

Super-Charged to attack cancer

• Opportunity to treat a wide variety of hematologic malignancies and solid tumors
• Better target killing through Increases in cytokine production
• Enhanced ADCC responds more robustly to antibody triggering
• Response by both KIR ligand matched and mismatched specificities allows inhibitory signals to be ignored
• A Phase 1/2 clinical trial of Memory NK cells showed them to be well-tolerated, persistent, and active against AML

WU-CART-007

Engineered to target T-cell cancers

• Opportunity to treat T-ALL, an orphan disease that is most common in children and young adults
• Deletion of the target in CAR-T prevents CAR-T Vs. CAR-T killing (friendly-fire)
• Disruption of the T-cell receptor enables the use of allogeneic donor T cells without risk of Graft Vs. Host Disease Use of healthy allogeneic donors prevents malignant T-cell contamination
• Use of allogeneic donors prevents malignant cell contamination
• Clinical trials testing the safety and efficacy of WU-CART-007 will soon begin enrolling patients

Next in our story

Scientific Publications

Next in our story

Scientific Publications